Outcome of cetuximab plus irinotecan in relation to RAS and BRAF mutational status in patients with colorectal cancer prior treated with a fluoropyrimidine, oxaliplatin and irinotecan

被引：0
|
作者：
Palshof, Jesper Andreas
Christensen, Troels Dreier
Poulsen, Tim Svendstrup
Jensen, Benny Vittrup
Linnemann, Dorte
Schou, Jakob Vasehus
Pfeiffer, Per
Yilmaz, Mette K. N.
Christensen, Ib Jarle
Hogdall, Estrid V.
Nielsen, Dorte
机构：
[1] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Oncol, Herlev, Denmark
[2] Herlev Univ Hosp, Dept Oncol, Herlev, Denmark
[3] Herlev Univ Hosp, Dept Pathol, Herlev, Denmark
[4] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Oncol, Copenhagen, Denmark
[5] Herlev Univ Hosp, Herlev, Denmark
[6] Odense Univ Hosp, Dept Oncol, Odense, Denmark
[7] Aalborg Univ Hosp, Dept Oncol, Aalborg, Denmark
[8] Herlev Hosp, Univ Copenhagen, Dept Pathol, Herlev, Denmark
[9] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Pathol, Herlev, Denmark
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e15115
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15115
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer
    Larsen, Finn Ole
    Pfeiffer, Per
    Nielsen, Dorte
    Skougaard, Kristin
    Qvortrup, Camilla
    Vistisen, Kirsten
    Fromm, Anne-Lene
    Jorgensen, Trine L.
    Bjerregaard, Jon K.
    Hoegdall, Estrid
    Jensen, Benny V.
    ACTA ONCOLOGICA, 2011, 50 (04) : 574 - 577
  • [32] Association of FcgRIIa and FcgRIIIa polymorphisms and kras mutations with clinical outcome in patients with metastatic colorectal cancer treated with cetuximab plus irinotecan
    Bibeau, F.
    Crapez, E.
    Di Fiore, F.
    Thezenas, S.
    Sabourin, J.
    Lamy, A.
    Frebourg, T.
    Michel, P.
    Ychou, M.
    Boissiere, F.
    ANNALS OF ONCOLOGY, 2008, 19 : 27 - 27
  • [33] REVERCE: Randomized Phase II Study of Regorafenib Followed by Cetuximab Versus the Reverse Sequence for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin, and Irinotecan
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 12 - 14
  • [34] Cetuximab every second week with irinotecan in patients with metastatic colorectal cancer refractory to 5-FU, oxaliplatin, and irinotecan: KRAS mutation status and efficacy
    Jensen, B. V.
    Schou, J. V.
    Johannesen, H. H.
    Christensen, I. J.
    Nielsen, D.
    Johansen, J. S.
    Hogdall, E. V.
    Larsen, O.
    Yilmaz, M.
    Pfeiffer, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients:The ELSIE study
    Robert Lim
    Seock-Ah Im
    Ruey-Kuen Hsieh
    Tsz Kok Yau
    Anthony Bonaventura
    Arkom Cheirsilpa
    Regina Esser
    Matthias Mueser
    Suresh Advani
    World Journal of Gastroenterology, 2011, 17 (14) : 1879 - 1888
  • [36] Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: The ELSIE study
    Lim, Robert
    Sun, Yan
    Im, Seock-Ah
    Hsieh, Ruey-Kuen
    Yau, Tsz Kok
    Bonaventura, Anthony
    Cheirsilpa, Arkom
    Esser, Regina
    Mueser, Matthias
    Advani, Suresh
    WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (14) : 1879 - 1888
  • [37] Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer
    Kemeny, N
    Tong, W
    Gonen, M
    Stockman, J
    Di Lauro, C
    Teitcher, J
    White, P
    Price, C
    Saltz, L
    Sharma, S
    Graham, MA
    ANNALS OF ONCOLOGY, 2002, 13 (09) : 1490 - 1496
  • [38] Retrospective RAS analysis of the EPIC trial: Cetuximab plus irinotecan vs irinotecan in patients (pts) with second-line metastatic colorectal cancer (mCRC)
    Sobrero, A.
    Lenz, H-J.
    Eng, C.
    Scheithauer, W.
    Middleton, G.
    Chen, W.
    Esser, R.
    Nippgen, J.
    Burris, H.
    ANNALS OF ONCOLOGY, 2018, 29 : 163 - 163
  • [39] Analysis of RAS/BRAF mutations in a randomized phase II WJOG6510G study of panitumumab plus irinotecan versus cetuximab plus irinotecan in chemorefractory metastatic colorectal cancer.
    Nishina, Tomohiro
    Taniguchi, Hiroya
    Sakai, Daisuke
    Kawakami, Hisato
    Sugimoto, Naotoshi
    Hara, Hiroki
    Esaki, Taito
    Denda, Tadamichi
    Makiyama, Akitaka
    Tsuda, Masahiro
    Okuda, Hiroyuki
    Izawa, Naoki
    Hosokawa, Ayumu
    Yamazaki, Kentaro
    Tokunaga, Shinya
    Moriwaki, Toshikazu
    Tsuji, Akihito
    Koh, Yasuhiro
    Kishimoto, Junji
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [40] Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL Study
    Wilke, Hansjochen
    Glynne-Jones, Robert
    Thaler, Josef
    Adenis, Antoine
    Preusser, Peter
    Aguilar, Enrique Aranda
    Aapro, Matti S.
    Esser, Regina
    Loos, Anja H.
    Siena, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) : 5335 - 5343
12345